Structural Determination of the Complement Inhibitory Domain of Borrelia Burgdorferi BBK32 Provides Insight into Classical Pathway Complement Evasion by Lyme Disease Spirochetes
Overview
Affiliations
The carboxy-terminal domain of the BBK32 protein from Borrelia burgdorferi sensu stricto, termed BBK32-C, binds and inhibits the initiating serine protease of the human classical complement pathway, C1r. In this study we investigated the function of BBK32 orthologues of the Lyme-associated Borrelia burgdorferi sensu lato complex, designated BAD16 from B. afzelii strain PGau and BGD19 from B. garinii strain IP90. Our data show that B. afzelii BAD16-C exhibits BBK32-C-like activities in all assays tested, including high-affinity binding to purified C1r protease and C1 complex, and potent inhibition of the classical complement pathway. Recombinant B. garinii BGD19-C also bound C1 and C1r with high-affinity yet exhibited significantly reduced in vitro complement inhibitory activities relative to BBK32-C or BAD16-C. Interestingly, natively produced BGD19 weakly recognized C1r relative to BBK32 and BAD16 and, unlike these proteins, BGD19 did not confer significant protection from serum killing. Site-directed mutagenesis was performed to convert BBK32-C to resemble BGD19-C at three residue positions that are identical between BBK32 and BAD16 but different in BGD19. The resulting chimeric protein was designated BXK32-C and this BBK32-C variant mimicked the properties observed for BGD19-C. To query the disparate complement inhibitory activities of BBK32 orthologues, the crystal structure of BBK32-C was solved to 1.7Å limiting resolution. BBK32-C adopts an anti-parallel four-helix bundle fold with a fifth alpha-helix protruding from the helical core. The structure revealed that the three residues targeted in the BXK32-C chimera are surface-exposed, further supporting their potential relevance in C1r binding and inhibition. Additional binding assays showed that BBK32-C only recognized C1r fragments containing the serine protease domain. The structure-function studies reported here improve our understanding of how BBK32 recognizes and inhibits C1r and provide new insight into complement evasion mechanisms of Lyme-associated spirochetes of the B. burgdorferi sensu lato complex.
Wulbern J, Windorfer L, Sato K, Nakao M, Hepner S, Margos G Ecol Evol. 2024; 14(5):e11397.
PMID: 38779535 PMC: 11109050. DOI: 10.1002/ece3.11397.
Damm A, Reyer F, Langhoff L, Lin Y, Falcone F, Kraiczy P Front Immunol. 2024; 15:1390468.
PMID: 38726006 PMC: 11079166. DOI: 10.3389/fimmu.2024.1390468.
Xu X, Herdendorf T, Duan H, Rohlik D, Roy S, Zhou H J Immunol. 2023; 212(4):689-701.
PMID: 38149922 PMC: 10872613. DOI: 10.4049/jimmunol.2300630.
Bencosme-Cuevas E, Kim T, Nguyen T, Berry J, Li J, Adams L Front Cell Infect Microbiol. 2023; 13:1253670.
PMID: 37965264 PMC: 10641286. DOI: 10.3389/fcimb.2023.1253670.
Antibody Cross-Reactivity in Serodiagnosis of Lyme Disease.
Grazlewska W, Holec-Gasior L Antibodies (Basel). 2023; 12(4).
PMID: 37873860 PMC: 10594444. DOI: 10.3390/antib12040063.